On Friday, Aclaris Therapeutics Inc (NASDAQ: ACRS) was 4.89% up from the session before settling in for the closing price of $1.84. A 52-week range for ACRS has been $1.05 – $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 15.24% over the past five years. When this article was written, the company’s average yearly earnings per share was at 70.18%. With a float of $92.29 million, this company’s outstanding shares have now reached $108.33 million.
Aclaris Therapeutics Inc (ACRS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aclaris Therapeutics Inc stocks. The insider ownership of Aclaris Therapeutics Inc is 14.81%, while institutional ownership is 72.89%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares.
Aclaris Therapeutics Inc (ACRS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.11 earnings per share (EPS) during the time that was less than consensus figure (set at -0.01) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.56% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
You can see what Aclaris Therapeutics Inc (ACRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.37, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ: ACRS) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 62.52%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 94.62%, which indicates a significant increase from 87.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0901 in the past 14 days, which was lower than the 0.0992 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6194, while its 200-day Moving Average is $1.9886. Nevertheless, the first resistance level for the watch stands at $2.0050 in the near term. At $2.0800, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1800. If the price goes on to break the first support level at $1.8300, it is likely to go to the next support level at $1.7300. The third support level lies at $1.6550 if the price breaches the second support level.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
There are 108,332K outstanding shares of the company, which has a market capitalization of 209.08 million. As of now, sales total 18,720 K while income totals -132,070 K. Its latest quarter income was 1,780 K while its last quarter net income were -15,430 K.
